AJTMH Transactions of the Royal Society of Tropical Medicine and Hygiene
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 60(4), 1999, pp. 526-532
Copyright © 1999 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Looareesuwan, S
Right arrow Articles by Hutchinson, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Looareesuwan, S
Right arrow Articles by Hutchinson, D.
Related Collections
Right arrow Malaria
Right arrow Plasmodium
American Journal of Tropical Medicine and Hygiene, Vol 60, Issue 4, 526-532
Copyright © 1999 by American Society of Tropical Medicine and Hygiene

Research Articles


Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand

S Looareesuwan, P Wilairatana, K Chalermarut, Y Rattanapong, CJ Canfield, and DB Hutchinson

The increasing frequency of therapeutic failures in falciparum malaria underscores the need for novel, rapidly effective antimalarial drugs or drug combinations. Atovaquone and proguanil are blood schizonticides that demonstrate synergistic activity against multi-drug-resistant Plasmodium falciparum in vitro. In an open-label, randomized, controlled clinical trial conducted in Thailand, adult patients with acute P. falciparum malaria were randomly assigned to treatment with atovaquone and proguanil/hydrochloride (1,000 mg and 400 mg, respectively, administered orally at 24-hr intervals for three doses) or mefloquine (750 mg administered orally, followed 6 hr later by an additional 500-mg dose). Efficacy was assessed by cure rate (the percentage of patients in whom parasitemia was eliminated and did not recur during 28 days of follow-up), parasite clearance time (PCT), and fever clearance time (FCT). Safety was assessed by sequential clinical and laboratory assessments for 28 days. Atovaquone/proguanil was significantly more effective than mefloquine (cure rate 100% [79 of 79] vs. 86% [68 of 79]; P < 0.002). The atovaquone/proguanil and mefloquine treatments did not differ with respect to PCT (mean = 65 hr versus 74 hr) or FCT (mean = 59 hr versus 51 hr). Adverse events were generally typical of malaria symptoms and each occurred in < 10% of the patients in either group, with the exception of increased vomiting found in the atovaquone/proguanil group. Transient elevations of liver enzyme levels occurred more frequently in patients treated with atovaquone/proguanil than with mefloquine, but the differences were not significant and values returned to normal by day 28 in most patients. The combination of atovaquone and proguanil was well tolerated and more effective than mefloquine in the treatment of acute uncomplicated multidrug-resistant falciparum malaria in Thailand.


This article has been cited by other articles:


Home page
 JAMAHome page
K. S. Griffith, L. S. Lewis, S. Mali, and M. E. Parise
Treatment of Malaria in the United States: A Systematic Review
JAMA, May 23, 2007; 297(20): 2264 - 2277.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
S. KRUDSOOD, S. N. PATEL, N. TANGPUKDEE, W. THANACHARTWET, W. LEOWATTANA, K. PORNPININWORAKIJ, A. K. BOGGILD, S. LOOAREESUWAN, and K. C. KAIN
EFFICACY OF ATOVAQUONE-PROGUANIL FOR TREATMENT OF ACUTE MULTIDRUG-RESISTANT PLASMODIUM FALCIPARUM MALARIA IN THAILAND
Am J Trop Med Hyg, April 1, 2007; 76(4): 655 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
A. K. BOGGILD, M. E. PARISE, L. S. LEWIS, and K. C. KAIN
ATOVAQUONE-PROGUANIL: REPORT FROM THE CDC EXPERT MEETING ON MALARIA CHEMOPROPHYLAXIS (II)
Am J Trop Med Hyg, February 1, 2007; 76(2): 208 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. A. Biagini, P. Viriyavejakul, P. M. O'Neill, P. G. Bray, and S. A. Ward
Functional Characterization and Target Validation of Alternative Complex I of Plasmodium falciparum Mitochondria.
Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1841 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
S. Ranque, B. Marchou, D. Malvy, E. Adehossi, R. Laganier, H. Tissot-Dupont, A. Lotte, S. Dydymsky, J. Durant, J.-P. Stahl, et al.
Treatment of imported malaria in adults: a multicentre study in France
QJM, October 1, 2005; 98(10): 737 - 743.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. K. Baird
Effectiveness of Antimalarial Drugs
N. Engl. J. Med., April 14, 2005; 352(15): 1565 - 1577.
[Full Text] [PDF]

Home page
 NEJMHome page
E. Schwartz, M. Parise, P. Kozarsky, and M. Cetron
Delayed Onset of Malaria -- Implications for Chemoprophylaxis in Travelers
N. Engl. J. Med., October 16, 2003; 349(16): 1510 - 1516.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
F. Marra, J. R Salzman, and M. H. Ensom
Atovaquone-Proguanil for Prophylaxis and Treatment of Malaria
Ann. Pharmacother., September 1, 2003; 37(9): 1266 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Jones and S. A. Ward
Biguanide-Atovaquone Synergy against Plasmodium falciparum In Vitro
Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2700 - 2703.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. L. Baggish and D. R. Hill
Antiparasitic Agent Atovaquone
Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1163 - 1173.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Society of Tropical Medicine and Hygiene.